I. COMMENCED TRADING IN NOVEMBER |
||||||||
Company (Symbol) | Date Filed | Date Comm. | Shares/ Units (M) | Price | Shares Out | Lead, Other Underwriters | Gross (M) | Post-Offering Market Cap (M) |
|
||||||||
INITIAL OFFERINGS |
||||||||
There were no initial public offerings conducted in November. |
||||||||
Total: $0M |
||||||||
Number of IPOs in November: 0 |
||||||||
Average value of November IPOs: $0M |
||||||||
Number of IPOs in 2002: 4 |
||||||||
Total raised in IPOs in 2002: $464.7M* |
||||||||
Average value of IPOs in 2002: $116.19M* |
||||||||
* Figures include an overallotment option exercised in January as part of a 2001 IPO. |
||||||||
Figures do not include an IPO conducted in June by YM BioSciences Inc. because the shares were privately placed. |
||||||||
|
||||||||
FOLLOW-ON OFFERINGS |
||||||||
Company (Symbol)# | Date Filed | Date Comm. | Shares/ Units (M) | Price | Shares Out | Lead, Other Underwriters | Gross (M) | Post-Offering Market Cap (M)@ |
| ||||||||
Myriad Genetics Inc. (MYGN)1 | 11/9/01 | 11/22/02 | 3S | $19.50 | 26.96 | Morgan Stanley | $58.5 | $525.72 |
|
||||||||
Total: $58.5M |
||||||||
Number of follow-on offerings in November: 1 |
||||||||
Average value of November follow-ons: $58.5M |
||||||||
Number of follow-on offerings in 2002: 21 |
||||||||
Total raised in follow-ons in 2002: $924.85M |
||||||||
Average value of follow-ons in 2002: $44.04M |
||||||||
|
||||||||
Notes: |
||||||||
# Unless otherwise indicated, shares are traded on the Nasdaq exchange. |
||||||||
% This column reflects the shares outstanding following the offering, when disclosed. |
||||||||
@ Market capitalization calculated is based on the offering price. |
||||||||
1. Myriad raised $57.3M net through a pursuant offering of 3M shares of stock. |
||||||||
|
||||||||
II. FILED AND PENDING |
||||||||
Company | Date Filed | Shares/ Units (M) | Price Range | Shares Out (M)% | Lead, Other Underwriters | Value (M) |
||
|
||||||||
INITIAL OFFERINGS |
||||||||
DiaDexus Inc. | 11/20/00 | 7S | $12-14 | 31.1 | Lehman Brothers; CIBC World Markets Robertson Stephens; Fidelity Capital Markets | $91 |
||
MitoKor Inc. | 3/8/02 | N/A | N/A | N/A | RBC Capital Markets Lazard Freres; Legg Mason Wood Walker; Gerard Klauer Mattison | $60 |
||
Novirio | 4/12/02 | N/A | N/A | N/A | Goldman, Sachs (co-lead); Banc of America Securities (co-lead); JP Morgan Securities; U.S. Bancorp Piper Jaffray | $115 |
||
Stem Genetics | 7/18/02 | 1.5S | $7 | 32.3 | Self-underwritten | $10.5 |
||
ViaCell Inc. | 1/30/02 | N/A | N/A | N/A | UBS Warburg; Banc of America Securities; U.S. Bancorp Piper Jaffray | $115 |
||
|
||||||||
FOLLOW-ON OFFERINGS |
||||||||
Amylin | 11/19/02 | N/A | N/A | N/A | N/A | $175 |
||
|
||||||||
Antex Biologics | 11/22/02 | 8U | $0.75 | 20.4 | Roan/Meyers & | $6 |
||
|
||||||||
Antigenics Inc. | 6/13/02 | N/A | N/A | 33.1 | N/A | $100 |
||
| ||||||||
Aphton Corp. | 7/8/02 | 5S | $6.50 | 25.1 | N/A | $32.5 |
||
| ||||||||
Ariad Pharmaceuticals | 1/9/02 | 3S | $5.28 | 35.4 | N/A | $15.84 |
||
| ||||||||
AtheroGenics | 11/13/02 | N/A | N/A | N/A | N/A | $75 |
||
| ||||||||
Biomira Inc. | 5/2/02 | N/A | N/A | 53.4 | N/A | C$150 (US$97.84) |
||
| ||||||||
Bioxel Pharma | 11/11/02 | N/A | N/A | N/A | Dundee Securities Corp.; National Bank Financial Inc.; Canaccord Capital Corp. | N/A |
||
| ||||||||
Celgene Corp. | 12/21/01 | N/A | N/A | 75.6 | N/A | $500 |
||
| ||||||||
Cell Pathways | 2/7/01 | N/A | N/A | N/A | N/A | $25 |
||
| ||||||||
Cepheid Inc. | 12/21/01 | N/A | N/A | 26.56 | N/A | $35 |
||
| ||||||||
Cerus Corp. | 8/13/01 | N/A | N/A | 15.7 | N/A | $300 |
||
| ||||||||
CollaGenex Pharmaceuticals | 10/26/01 | 0.965S | $8.01 | N/A | Kingsbridge Capital; | $7.7 |
||
| ||||||||
Cytogen Corp. | 10/26/01 | 10S | $2.50 | 79.8 | N/A | $25 |
||
| ||||||||
Dyax Corp. | 4/25/02 | 5S | $3.66 | 19.6 | N/A | $18.3 |
||
| ||||||||
EntreMed Inc. | 5/10/02 | N/A | N/A | N/A | N/A | $50 |
||
| ||||||||
Epimmune Inc. | 10/25/02 | 7.25S | $1.32 | 19.4 | Punk Ziegel & Co. | $9.57 |
||
| ||||||||
Exelixis Inc. | 7/30/01 | N/A | N/A | 49.2 | N/A | $150 |
||
| ||||||||
Genaera Corp. | 11/21/01 | N/A | N/A | 38.9 | N/A | $50 |
||
| ||||||||
Genaissance Pharmaceuticals | 10/18/01 | N/A | N/A | 22.8 | N/A | $35 |
||
| ||||||||
Geron Corp. | 1/30/02 | N/A | N/A | N/A | N/A | $150 |
||
| ||||||||
Hollis-Eden Pharmaceuticals | 2/26/02 | 3S | $8.71 | N/A | N/A | $26.13 |
||
| ||||||||
InSite Vision | 2/2/01 | N/A | N/A | N/A | Ladenburg Thalmann | $40 |
||
| ||||||||
Lexicon Genetics | 11/27/02 | 12S | $3.98 | N/A | N/A | $47.76 |
||
| ||||||||
NeoTherapeutics | 1/3/01 | N/A | N/A | 26.9 | N/A | $50 |
||
| ||||||||
Neurogen Corp. | 8/16/02 | N/A | N/A | N/A | N/A | $75 |
||
| ||||||||
Northwest Biotherapeutics | 6/4/02 | 11S | $3.77 | 17 | C.E. Unterberg, | $41.5 |
||
| ||||||||
Pharmos Corp. | 2/4/02 | N/A | N/A | 56.6 | N/A | $25 |
||
| ||||||||
SciClone Pharmaceuticals | 11/6/01 | N/A | N/A | N/A | N/A | $20 |
||
| ||||||||
StemCells Inc. | 3/8/02 | 15S | $2.52 | 25.8 | N/A | $37.8 |
||
| ||||||||
Targeted | 12/13/01 | 8.84S | $2.57 | N/A | N/A | $22.72 |
||
| ||||||||
Triangle Pharmaceuticals | 9/25/02 | N/A | N/A | N/A | N/A | $80 |
||
| ||||||||
Tularik Inc. | 8/14/01 | N/A | N/A | 49.2 | N/A | $250 |
||
| ||||||||
VaxGen Inc. | 11/7/02 | N/A | N/A | N/A | N/A | $150 |
||
|
||||||||
III. WITHDRAWN AND POSTPONED |
||||||||
Company | Date Filed/ Date Pulled | Shares/ Units (M) | Price Range | Shares Out (M) | Lead, Other | Value (M) |
||
|
||||||||
FOLLOW-ON OFFERINGS |
||||||||
Advanced Tissue Sciences Inc. | 6/12/02 11/5/02 | 10S | $1.07 | N/A | N/A | $10.7 |
||
|
||||||||
Notes: |
||||||||
# Unless otherwise indicated, shares are traded on the Nasdaq exchange. |
||||||||
* Stock symbols for companies seeking to complete IPOs are proposed. |
||||||||
% This column reflects the shares outstanding following the offering, when disclosed. |
||||||||
N/A = Not available, applicable or reported. |
||||||||
AMEX = American Stock Exchange; CDNX = Canadian Venture Exchange; TSE = Toronto Stock Exchange |
||||||||
1. DiaDexus' IPO value, $91M, is based on the sale of 7M shares at $13 each, the midpoint of the expected price range. The underwriters have an overallotment option on 1.05M shares. |
||||||||
2. MitoKor filed for an IPO to raise $60M. |
||||||||
3. Novirio filed for an IPO to raise $115M. |
||||||||
4. Stem Genetics filed for an IPO to raise $10.5M. It intends to go public on the Over-the-Counter Bulletin Board, but did not specify a proposed symbol in its SEC filing. |
||||||||
5. ViaCell filed for a $115M IPO. No further details were disclosed. |
||||||||
6. Amylin filed a shelf registration with the SEC that would allow it to issue from time to time up to $175M of common stock. |
||||||||
7. Antex filed a registration statement with the SEC for a proposed public offering of units each consisting of one share of common stock and one redeemable stock purchase warrant to purchase one share of common stock. |
||||||||
8. Antigenics filed a shelf registration statement covering the issuance of common and preferred stock, as well as secured and unsecured debt securities, up to $60M. It also had a previous registration with $40M in securities remaining. |
||||||||
9. Aphton filed a shelf registration statement to sell up to 5M shares at a maximum amount of $6.50 per share. The company privately placed 2.5M shares worth $5M in September. |
||||||||
10. Ariad filed a shelf registration statement to sell up to 3M shares. At the Jan. 8 closing stock price, it would raise $15.84M. |
||||||||
11. AtheroGenics filed with the SEC a shelf registration statement to permit the firm to offer and sell up to $75M of common stock. |
||||||||
12. Biomira filed for a $150M shelf prospectus in Canada. |
||||||||
13. Bioxel filed a preliminary prospectus for a public offering of common shares in Canada. There will be an overallotment option for 15% of the shares offered. |
||||||||
14. Celgene filed a universal shelf registration statement to offer and sell common stock, debt securities and convertible debt securities, up to a total value of $500M. |
||||||||
15. Cell Pathways filed a shelf registration statement for the sale of $25M in common stock. The company privately placed $4.4M in shares in September. |
||||||||
16. Cepheid filed a shelf registration statement to offer and sell up to $35M of its common stock, preferred stock, debt securities and warrants. |
||||||||
17. Cerus filed to sell up to $300M of common stock and debt in a shelf offering. |
||||||||
18. The value of CollaGenex's proposed offering, $7.7M, is based on the Oct. 26 closing stock price of $8.01. CollaGenex privately placed 119,335 shares in May, raising $1M. It placed 32,187 shares in June, raising $266,667. |
||||||||
19. Cytogen filed to offer 10M shares at about $2.50 each in a shelf registration statement. It privately placed 3M shares in January, and another 4.17M shares in June. |
||||||||
20. Dyax filed a shelf registration statement to sell up to 5M shares. The value, $18.3M, is based on the April 24 closing stock price, $3.66. |
||||||||
21. EntreMed filed a $50M shelf registration statement, allowing it to offer securities from time to time in the form of common stock, preferred stock or warrants to purchase securities. |
||||||||
22. Epimmune filed to sell 7.25M shares at $1.32 per share for $9.57M. |
||||||||
23. Exelixis filed a shelf registration statement to sell up to $150M in common stock. |
||||||||
24. Genaera filed a universal shelf registration statement for the sale of up to $50M in common stock, preferred stock or warrants to purchase common stock or preferred stock. It privately placed $16.5M in shares in April. |
||||||||
25. Genaissance filed a shelf registration statement to offer and sell common stock, preferred stock, debt or warrants, up to a value of $35M. |
||||||||
26. Geron filed a prospectus for the sale of up to $150M in debt securities, common or preferred stock and warrants. |
||||||||
27. Hollis-Eden filed a shelf registration statement to sell up to 3M shares and warrants from time to time. The value is based on the proposed maximum offering price. |
||||||||
28. InSite filed a shelf registration statement in February 2001 to sell $40M in stock. |
||||||||
29. Lexicon Genetics filed a shelf registration statement with the SEC to sell up to an aggregate of 12M shares of common stock from time to time. |
||||||||
30. NeoTherapeutics filed a shelf registration statement covering the sale of debt securities, common stock, preferred stock, depository shares or warrants up to $50M. Since May of 2001, it has privately placed $27.14M. |
||||||||
31. Neurogen filed for a $75M universal shelf registration statement. |
||||||||
32. Northwest expects to offer 11M shares as part of a lock-up agreement with the underwriter from the company's December initial public offering. The value, $41.5M, is based on the June 3 closing stock price of $3.77. |
||||||||
33. Pharmos filed a shelf registration statement to sell up to $25M of common stock, preferred stock, debt securities and/or warrants. |
||||||||
34. SciClone filed to sell up to $20M in common and preferred stock, debt securities and warrants from time to time through a shelf offering. SciClone privately placed $10.62M in shares in June. |
||||||||
35. StemCells filed with the SEC to sell up to 15M shares to raise a maximum of $37.8M. Further details were not disclosed. |
||||||||
36. Targeted Genetics filed a shelf registration statement for the sale of up to about 8.84M shares of common stock. The value is based on the Jan. 22 closing stock price of $2.57. |
||||||||
37. Triangle filed a shelf registration with the SEC to sell up to $80M in common and preferred stock. |
||||||||
38. Tularik filed to sell up to $250M in common stock and debt securities. It raised $27.2M in October with an offering of 4M shares. |
||||||||
39. VaxGen filed a shelf registration statement for $150M in common stock, preferred stock, debt securities and warrants. Further details were not disclosed. |
||||||||
40. Advanced Tissue withdrew the offering in December due to market conditions. |